Results 211 to 220 of about 246,725 (308)

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

open access: yesObesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu   +13 more
wiley   +1 more source

Clinical use of immunosuppressants [PDF]

open access: yes, 2005
Fung, JJ   +3 more
core  

Beyond BMI: The Impact of the New Lancet Commission Diagnostic Criteria on Prevalence of Obesity in the United States

open access: yesObesity, EarlyView.
ABSTRACT Objective This study compared population characteristics and overall US prevalence of obesity over time using the BMI criteria and the 2025 Lancet Commission criteria (i.e., the Excess Adiposity criteria). Methods We analyzed data from 58,053 adults aged ≥ 20 years in the National Health and Nutrition Examination Survey from 1999 to 2023.
Jennifer H. Hwang, Neda Laiteerapong
wiley   +1 more source

Incidence of cognitive impairment post first stroke: a systematic review and meta-analysis. [PDF]

open access: yesFront Neurol
Zhang X   +8 more
europepmc   +1 more source

Pre‐Existing Nocturia Status Predicts Bladder Symptom Exacerbation Following COVID‐19 Vaccination in Women

open access: yes
The Kaohsiung Journal of Medical Sciences, EarlyView.
Hsien‐Che Ou   +3 more
wiley   +1 more source

Twenty‐Four Month Outcomes From a Real‐World Telehealth Obesity Treatment Clinic Using Obesity Medications

open access: yesObesity, EarlyView.
ABSTRACT Objective Antiobesity medications (AOMs) are indicated for long‐term use; however, evidence of their real‐world long‐term efficacy is limited. This study describes clinical outcomes from 18‐ and 24‐month use of AOMs in a telemedicine weight management clinic.
Kathleen R. Ruddiman   +7 more
wiley   +1 more source

Weight Loss With GLP‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis

open access: yesObesity, EarlyView.
ABSTRACT Objective Two glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) (semaglutide and liraglutide) and one dual agonist (tirzepatide) are FDA‐approved for weight loss in adults with obesity without type 2 diabetes mellitus. This systematic review and network meta‐analysis aims to compare the efficacy of these agents against each other.
Michael Lim   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy